RC220 cGMP Manufacturing Complete

Race Oncology announces that a Certificate of Analysis (CoA) has been issued for the first cGMP batch of bisantrene formulation, RC220

Confirms RC220 meets all cGMP specifications required for a human IV drug product for clinical use

Ardena was contracted to manufacture RC220 to meet the exacting standards required by global regulatory authorities for human clinical use, including the European Medicines Agency (EMA), the US Food & Drug Administration (FDA) and the Australian Therapeutic Goods Administration (TGA)

Major milestone in the progress of RC220 for use in human clinical trials

The GLP toxicity testing will be completed in the coming months